AMINOLOGICS CO.,LTD. Logo

AMINOLOGICS CO.,LTD.

Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.

074430 | KO

Overview

Corporate Details

ISIN(s):
KR7074430000
LEI:
Country:
South Korea
Address:
서울특별시 강남구 역삼로 151 삼오빌딩3층 301호, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AMINOLOGICS CO., LTD. is a specialty manufacturer of amino acids and their derivatives. The company focuses on producing high-purity chiral amino acids using its proprietary and patented platform technology, ARCA (Alanine Racemase Chiral). This innovative technology allows for the cost-effective separation and production of amino acids with high optical purity. AMINOLOGICS supplies these amino-acid-based raw materials, including Active Pharmaceutical Ingredients (APIs), to various industrial fields such as pharmaceuticals, fine chemicals, agrochemicals, and the food and feed industries, catering to both research and large-scale production needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-07-04 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 66.7 KB
2025-06-30 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-06-26 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 86.7 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 930.5 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.1 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 24.8 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.3 MB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 157.5 KB
2025-03-10 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 138.0 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.7 KB
2025-02-27 00:00
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 18.6 KB
2025-01-31 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 10.9 KB
2024-12-12 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-08 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 944.5 KB

Automate Your Workflow. Get a real-time feed of all AMINOLOGICS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AMINOLOGICS CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AMINOLOGICS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.